Review



optic grid fluorescent microscopy  (Evident Corporation)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Evident Corporation optic grid fluorescent microscopy
    The two patients' Epstein-Barr virus-transformed cells were treated with gentamicin (1000 µg/ml) for 5 days. Cells were cytospun, fixed and immunostained with mouse monoclonal anti integrin β2 (CD18) antibody (Santa Cruz Biotechnology Inc., USA). Slides were mounted using immunofluorescence and DAPI for nuclear staining and analyzed by <t>optic</t> <t>grid</t> fluorescence <t>microscopy</t> (Olympus). a. 1000-fold magnification of healthy control's Epstein-Barr virus-transformed lymphocytes b. 600-fold magnification of gentamicin untreated (upper panel) and treated (lower panel) lymphoblastoids derived from patients 1 and 2. c. 1000-fold magnification of gentamicin untreated (left panel) and treated (right panel) lymphoblastoids derived from patient 1. N indicates nucleus; PM, plasma membrane; C, cytoplasm.
    Optic Grid Fluorescent Microscopy, supplied by Evident Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/optic+grid+fluorescent+microscopy/pmc02982813-96-15-19?v=Evident+Corporation
    Average 90 stars, based on 1 article reviews
    optic grid fluorescent microscopy - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "The Effect of Gentamicin-Induced Readthrough on a Novel Premature Termination Codon of CD18 Leukocyte Adhesion Deficiency Patients"

    Article Title: The Effect of Gentamicin-Induced Readthrough on a Novel Premature Termination Codon of CD18 Leukocyte Adhesion Deficiency Patients

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0013659

    The two patients' Epstein-Barr virus-transformed cells were treated with gentamicin (1000 µg/ml) for 5 days. Cells were cytospun, fixed and immunostained with mouse monoclonal anti integrin β2 (CD18) antibody (Santa Cruz Biotechnology Inc., USA). Slides were mounted using immunofluorescence and DAPI for nuclear staining and analyzed by optic grid fluorescence microscopy (Olympus). a. 1000-fold magnification of healthy control's Epstein-Barr virus-transformed lymphocytes b. 600-fold magnification of gentamicin untreated (upper panel) and treated (lower panel) lymphoblastoids derived from patients 1 and 2. c. 1000-fold magnification of gentamicin untreated (left panel) and treated (right panel) lymphoblastoids derived from patient 1. N indicates nucleus; PM, plasma membrane; C, cytoplasm.
    Figure Legend Snippet: The two patients' Epstein-Barr virus-transformed cells were treated with gentamicin (1000 µg/ml) for 5 days. Cells were cytospun, fixed and immunostained with mouse monoclonal anti integrin β2 (CD18) antibody (Santa Cruz Biotechnology Inc., USA). Slides were mounted using immunofluorescence and DAPI for nuclear staining and analyzed by optic grid fluorescence microscopy (Olympus). a. 1000-fold magnification of healthy control's Epstein-Barr virus-transformed lymphocytes b. 600-fold magnification of gentamicin untreated (upper panel) and treated (lower panel) lymphoblastoids derived from patients 1 and 2. c. 1000-fold magnification of gentamicin untreated (left panel) and treated (right panel) lymphoblastoids derived from patient 1. N indicates nucleus; PM, plasma membrane; C, cytoplasm.

    Techniques Used: Transformation Assay, Immunofluorescence, Staining, Fluorescence, Microscopy, Derivative Assay



    Similar Products

    optic grid fluorescent microscopy  (Evident Corporation)
    90
    Evident Corporation optic grid fluorescent microscopy
    The two patients' Epstein-Barr virus-transformed cells were treated with gentamicin (1000 µg/ml) for 5 days. Cells were cytospun, fixed and immunostained with mouse monoclonal anti integrin β2 (CD18) antibody (Santa Cruz Biotechnology Inc., USA). Slides were mounted using immunofluorescence and DAPI for nuclear staining and analyzed by <t>optic</t> <t>grid</t> fluorescence <t>microscopy</t> (Olympus). a. 1000-fold magnification of healthy control's Epstein-Barr virus-transformed lymphocytes b. 600-fold magnification of gentamicin untreated (upper panel) and treated (lower panel) lymphoblastoids derived from patients 1 and 2. c. 1000-fold magnification of gentamicin untreated (left panel) and treated (right panel) lymphoblastoids derived from patient 1. N indicates nucleus; PM, plasma membrane; C, cytoplasm.
    Optic Grid Fluorescent Microscopy, supplied by Evident Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/optic+grid+fluorescent+microscopy/pmc02982813-96-15-19?v=Evident+Corporation
    Average 90 stars, based on 1 article reviews
    optic grid fluorescent microscopy - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    The two patients' Epstein-Barr virus-transformed cells were treated with gentamicin (1000 µg/ml) for 5 days. Cells were cytospun, fixed and immunostained with mouse monoclonal anti integrin β2 (CD18) antibody (Santa Cruz Biotechnology Inc., USA). Slides were mounted using immunofluorescence and DAPI for nuclear staining and analyzed by optic grid fluorescence microscopy (Olympus). a. 1000-fold magnification of healthy control's Epstein-Barr virus-transformed lymphocytes b. 600-fold magnification of gentamicin untreated (upper panel) and treated (lower panel) lymphoblastoids derived from patients 1 and 2. c. 1000-fold magnification of gentamicin untreated (left panel) and treated (right panel) lymphoblastoids derived from patient 1. N indicates nucleus; PM, plasma membrane; C, cytoplasm.

    Journal: PLoS ONE

    Article Title: The Effect of Gentamicin-Induced Readthrough on a Novel Premature Termination Codon of CD18 Leukocyte Adhesion Deficiency Patients

    doi: 10.1371/journal.pone.0013659

    Figure Lengend Snippet: The two patients' Epstein-Barr virus-transformed cells were treated with gentamicin (1000 µg/ml) for 5 days. Cells were cytospun, fixed and immunostained with mouse monoclonal anti integrin β2 (CD18) antibody (Santa Cruz Biotechnology Inc., USA). Slides were mounted using immunofluorescence and DAPI for nuclear staining and analyzed by optic grid fluorescence microscopy (Olympus). a. 1000-fold magnification of healthy control's Epstein-Barr virus-transformed lymphocytes b. 600-fold magnification of gentamicin untreated (upper panel) and treated (lower panel) lymphoblastoids derived from patients 1 and 2. c. 1000-fold magnification of gentamicin untreated (left panel) and treated (right panel) lymphoblastoids derived from patient 1. N indicates nucleus; PM, plasma membrane; C, cytoplasm.

    Article Snippet: The slides were mounted using immunofluore containing 4′,6-diamidino-2-phenylindolem (DAPI) for nuclear staining, and analyzed by optic grid fluorescent microscopy (Olympus).

    Techniques: Transformation Assay, Immunofluorescence, Staining, Fluorescence, Microscopy, Derivative Assay